How is ceftobiprole used in Canada: the CLEAR study final results.
Ceftobiprole
MRSA infections
bacteremia
cephalosporins
endocarditis
pneumonia
Journal
Expert review of anti-infective therapy
ISSN: 1744-8336
Titre abrégé: Expert Rev Anti Infect Ther
Pays: England
ID NLM: 101181284
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR ( The authors review the final data using the national ethics approved CLEAR study. Thereafter the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024). In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP). In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.
Sections du résumé
BACKGROUND
UNASSIGNED
We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (
RESEARCH DESIGN AND METHODS
UNASSIGNED
The authors review the final data using the national ethics approved CLEAR study. Thereafter the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).
RESULTS
UNASSIGNED
In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).
CONCLUSIONS
UNASSIGNED
In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.
Identifiants
pubmed: 39008122
doi: 10.1080/14787210.2024.2374280
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM